An Open-Label, Two-Arm (DefenCath® vs. Institutional Standard of Care) Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to Less Than 18 Years of Age With Kidney Failure Receiving Hemodialysis Via a Central Venous Catheter

This study is a post-marketing approval requirement to assess the safety and time to Catheter-related Bloodstream Infections (CRBSI) of DefenCath in pediatric population (birth to less than 18 years of age) who are on chronic HD for kidney failure.

Start Date01 Apr 2025

Sponsor / Collaborator

CorMedix, Inc.

NCT06512233

/ Not yet recruitingNot ApplicableIIT

Dual Therapy Dilemma: Heparin Alone vs. Heparin-Aspirin Combo in Free Flap Survival

This randomized clinical trial aims to compare the effectiveness of heparin alone versus combination therapy of Heparin- Aspirin in improving free flap survival in patients undergoing reconstructive surgery. Participants will be randomly assigned to receive either heparin or a combination therapy, and the primary outcome measure will be the survival rate of the free flap at various time points post-surgery

Start Date01 Jan 2025

Sponsor / Collaborator

Aga Khan University

NCT06662253

/ Not yet recruitingPhase 2/3IIT

Anti-Xa Guided Dosing of Low Molecular Weight Heparin for Prevention of Venous Thromboembolism Following Traumatic Injury: a Multicentre Pilot Randomized Trial

This multicentre pilot trial will assess the feasibility of a full-scale, randomized trial to determine whether bloodwork guided dosing of blood thinners reduces the risk of clotting in high-risk trauma patients. Patients will receive either standard of care dosing or dosing with adjustments based on bloodwork to achieve a minimum therapeutic threshold.

Start Date01 Jan 2025

Sponsor / Collaborator

Ottawa Hospital Research Institute

100 Clinical Results associated with Heparin Sodium

100 Translational Medicine associated with Heparin Sodium

100 Patents (Medical) associated with Heparin Sodium

5,399

Literatures (Medical) associated with Heparin Sodium

31 Dec 2025·ANNALS OF MEDICINE

Low-dose heparin sodium as a protective factor against bronchiolitis obliterans formation after adenovirus infection

Article

Author: Hu, Rong ; Cui, Lei ; Ding, Xiaofang ; Peng, Li ; Zhong, Lili ; Lin, Lin ; Huang, Han ; Liu, Silan ; Chen, Min

BACKGROUND:

Adenovirus (ADV) pneumonia in children is a significant contributor to the occurrence of post-infectious bronchiolitis obliterans (BO). Heparin sodium has known anti-inflammatory, immunomodulatory, and tissue repair properties. However, its role in treating BO after ADV infection remains unclear.

METHODS:

A retrospective analysis was conducted on 793 children diagnosed with ADV pneumonia and hospitalized in the southern region from January 2019 to December 2019. Among them, 307 cases were classified as single ADV pneumonia. We utilized directed acyclic graphs to analyze the causal relationships between various variables, which further helped us identify the independent and confounding variables for constructing our regression model. Propensity score matching (PSM) was also employed to control for confounding variables that could not be intervened in this study, ensuring baseline level equilibrium and correction. We utilized univariate logistic regression analysis to explore the factors influencing BO development after ADV pneumonia.

RESULTS:

Among the 793 children diagnosed with ADV pneumonia, 86 cases (10.84%) progressed to BO. The proportion of heparin use was higher in the non-BO group than in the BO group after PSM. The univariate regression analysis revealed that acute respiratory failure, neurological involvement and fibrinogen (FIB) were risk factors for the development of BO in ADV pneumonia cases (OR > 1, p < 0.05), but low-dose heparin sodium treatment and hemoglobin (OR < 1, p < 0.05) exhibited protective effects against BO formation. Among the 307 children with single ADV pneumonia (excluding confounding factors), 33 cases (10.75%) developed BO. The univariate regression analysis further indicated that fever duration, acute respiratory failure and FIB were risk factors for the development of BO in single ADV pneumonia (OR > 1, p < 0.05), while low-dose heparin sodium treatment (OR < 1, p < 0.05) was protective against BO formation after a single ADV pneumonia.

CONCLUSION:

Low-dose heparin sodium treatment may be a protective factor against the development of BO after ADV pneumonia infection.

01 Apr 2025·SEMINARS IN THROMBOSIS AND HEMOSTASIS

Pharmacotherapy for Venous Thromboprophylaxis following Total Hip or Knee Arthroplasty: A Systematic Review and Network Meta-analysis

Review

Author: Ramanathan, Kollengode ; Li, Ruiqi ; Yong, Bryan Song Jun ; Ling, Ryan Ruiyang ; Poh, Jane Wenjin ; Ho, Sean Wei Loong ; Fan, Bingwen Eugene ; Rochwerg, Bram ; Arya, Roopen ; Tan, Chuen Seng

Abstract:

The optimal pharmacological prophylaxis for venous thromboembolism (VTE) after hip or knee arthroplasty is uncertain. We conducted a systematic review and network meta-analysis to compare the efficacy and safety of various medications. We searched multiple databases for randomized clinical trials (RCTs) comparing medications (including factor Xa inhibitors, factor IIa inhibitor, warfarin, unfractionated heparin [UFH], low-molecular-weight heparin [LMWH], aspirin, pentasaccharide) for VTE prophylaxis post-arthroplasty. Outcomes included any postoperative VTE identified with screening, major bleeding, and death. We used LMWH as the main comparator for analysis and performed trial sequential analysis (TSA) for each pairwise comparison. Certainty of evidence was assessed using GRADE (Grading of Recommendations, Assessments, Developments and Evaluations). We analyzed 70 RCTs (55,841 participants). Factor Xa inhibitors decreased postoperative VTE significantly compared with LMWH (odds ratio [OR]: 0.55, 95% confidence interval [CI]: 0.44–0.68, high certainty). Pentasaccharides probably reduce VTE (OR: 0.61, 95% CI: 0.36–1.02, moderate certainty), while the factor IIa inhibitor dabigatran may reduce VTE (OR: 0.75, 95% CI: 0.40–1.42, low certainty). UFH probably increases VTE compared with LMWH (OR: 1.31, 95% CI: 0.91–1.89, moderate certainty), and other agents like warfarin, aspirin, placebo, and usual care without thromboprophylaxis increase VTE (high certainty). Factor Xa inhibitors may not significantly affect major bleeding compared with LMWH (OR: 1.06, 95% CI: 0.81–1.39, low certainty). No medications had a notable effect on mortality compared with LMWH (very low certainty). TSA suggests sufficient evidence for the benefit of factor Xa inhibitors over LMWH for VTE prevention. Compared with LMWH and aspirin, factor Xa inhibitors are associated with reduced VTE after hip or knee arthroplasty, without an increase in bleeding and likely no impact on mortality.

01 Mar 2025·ARTIFICIAL ORGANS

Anti‐factor Xa and activated partial thromboplastin time strategies for unfractionated heparin dosing after HeartMate 3 left ventricular assist device implantation

Article

Author: Yuzefpolskaya, Melana ; Powley, Tanner R. ; Sutherland, Lauren D. ; Yang, Christine G. ; Kurlansky, Paul A. ; Hynds, Melissa A. ; Hastie, Jonathan M. ; Takeda, Koji ; Feng, Iris ; Sayer, Gabriel T. ; Colombo, Paolo C. ; Naka, Yoshifumi ; Eisenberger, Andrew ; Uriel, Nir Y.

Abstract:

Background:

No clear guidelines exist for perioperative anticoagulation management after durable left ventricular assist device insertion. In this study, we sought to compare outcomes between anti‐factor Xa (FXa) and activated partial thromboplastin time (aPTT) in monitoring unfractionated heparin (UFH) dosing after HeartMate 3 (HM3) insertion.

Methods:

This is a single‐center retrospective review of patients who received UFH after HM3 insertion between 01/2020–12/2022. Post‐operative UFH dose was titrated by aPTT goal 45–60 sec (n = 53) or FXa goal 0.1–0.2 U/mL (n = 59). Baseline differences between cohorts were balanced by inverse probability treatment weighting.

Results:

At baseline, unadjusted FXa patients were more likely to be white (47.5% vs. 35.8%, p < 0.001), INTERMACS 1–2 (69.5% vs. 47.2%, p = 0.013), have history of coronary artery disease (66.1% vs. 43.4%, p = 0.026), and lower eGFR (54.1 vs. 63.7 mL/min/1.73 m2, p = 0.029) compared to the aPTT group. After adjusting for several bleeding/thrombosis risk factors, 97.5% of FXa and 91.0% of aPTT patients reached therapeutic levels with comparable UFH duration and maximum dose. Moreover, in‐hospital mortality (2.5% vs. 3.1%, p = 0.842), major bleeding events (4.2% vs. 9.2%, p = 0.360), and thromboembolic events (21.8% vs. 10.1%, p = 0.151) remained without significant differences between FXa and aPTT cohorts. There was a high degree of variability in FXa (r2 = 0.20) and aPTT (r2 = 0.22) values for any given UFH dose.

Conclusions:

No differences in frequency of bleeding or thromboembolic events were observed in this study between FXa versus aPTT cohorts after HM3 implantation. More longitudinal studies are warranted to determine whether or not one assay is superior to the other.

News (Medical) associated with Heparin Sodium

26 Dec 2024

·www.drugs.com

Therapeutic-Dose Anticoagulation Linked to Lower Mortality in COVID-19

THURSDAY, Dec. 26, 2024 -- For patients hospitalized for COVID-19 , administration of therapeutic-dose versus prophylactic-dose anticoagulation with heparins is associated with lower 28-day mortality, according to a review published online Dec. 24 in the Annals of Internal Medicine . Claire L. Vale, Ph.D., and colleagues from the World Health Organization Rapid Evidence Appraisal for COVID-19 Therapies Working Group, estimated the association of higher-dose versus lower-dose anticoagulation with clinical outcomes for patients hospitalized with COVID-19 using data from 20 eligible trials and two additional studies. The researchers found that 28-day mortality was reduced with therapeutic-dose versus prophylactic-dose anticoagulation with heparins (odds ratio, 0.77; 95 percent confidence interval, 0.64 to 0.93; 11 trials included 6,297 patients, 5,456 of whom required low or no oxygen at randomization). For 28-day mortality, the odds ratios were 1.21 (95 percent confidence interval, 0.93 to 1.58) for therapeutic-dose versus intermediate-dose anticoagulation and 0.95 (95 percent confidence interval, 0.76 to 1.19) for intermediate- versus prophylactic-dose anticoagulation. Across predefined patient subgroups, treatment effects were broadly consistent; some analyses were limited in power. Fewer thromboembolic events were seen in association with higher- versus lower-dose anticoagulation, but the risk for major bleeding was greater. "For each comparison, higher- compared with lower-dose anticoagulation was associated with fewer thromboembolic events but a greater risk for major bleeding," the authors write.

Clinical ResultClinical StudyAHA

19 Dec 2024

·www.prnewswire.com

BGM Group and Jointown Deepen Cooperation, Ushering in a New Era of Pharmaceutical Development

CHENGDU, China, Dec. 19, 2024 /PRNewswire/ -- BGM Group Ltd. (NASDAQ: BGM) ("the Company" or "BGM"), Mr. Xin Zhanchang, Chairman of the Board of Directors of BGM Group and Chairman of Gansu Qilianshan Pharmaceutical Co., Ltd., led the sales team to visit their long-term strategic partner, Jointown Pharmaceutical Group. They were warmly welcomed by Mr. Liu Shulin, one of the founders and Honorary Vice Chairman of Jointown, along with Vice Chairman Mr. Liu Dengpan and other senior executives. The two sides held a cordial, productive meeting, further consolidating and deepening their strategic partnership. They also signed a strategic cooperation agreement for Qilianshan Pharmaceutical's licorice fluid extract and Gandixin (Compound Licorice Tablets) series products. Jointown Pharmaceutical Group, as a leading enterprise in China's pharmaceutical industry with the most extensive sales network, focuses on Western medicine, traditional Chinese medicine, and medical devices. It is committed to providing medical institutions, wholesale companies, and retail pharmacies with pharmaceutical products, logistics, and other value-added services. Meanwhile, BGM Group has demonstrated exceptional performance in the research, development, production, and operation of its "Qilianshan" brand pharmaceutical products. The long-standing partnership between the two companies stems from their outstanding achievements in their respective fields and a shared commitment to development philosophies. Over the years, BGM Group and Jointown have demonstrated a high degree of synergy in several areas. First, in product research, development, production, and sales, Qilianshan Pharmaceutical, a subsidiary of BGM Group, leverages its strong R&D capabilities and advanced production technologies under the "Qilianshan" brand. Combined with Jointown's comprehensive sales network and logistics distribution system, BGM's products have gained widespread recognition and acceptance in domestic and international markets. Second, BGM Group's rigorous quality testing system ensures product safety and quality. Both companies share a commitment to customer service excellence, offering comprehensive after-sales support and prioritizing consumer satisfaction. Lastly, in market expansion and brand building, the two companies maintain close collaboration, enhancing the influence of both the BGM and Jointown brands. During the meeting, the two parties engaged in in-depth discussions on market demand, quality control, and sales channel expansion for licorice-based products. They agreed that as the pharmaceutical industry continues to evolve, consumer demand for high-quality, high-efficiency pharmaceutical products will grow significantly. Both companies are dedicated to driving product innovation and quality improvement to meet the diverse needs of the market. In the presence of both teams, BGM Group and Jointown signed a strategic cooperation agreement for the licorice fluid extract and Gandixin (Compound Licorice Tablets) series products. This agreement marks a new milestone in their collaboration in the pharmaceutical sector, particularly in licorice-based products, with injecting strong momentum into their future development. Both parties reaffirmed their commitment to maintaining a close partnership and contributing to the prosperity and advancement of the pharmaceutical industry. This successful meeting between BGM Group and Jointown Pharmaceutical Group not only further solidified their strategic partnership but also paved the way for broader opportunities for future cooperation. Together, BGM Group and Jointown are poised to create an even brighter chapter in the pharmaceutical industry. Attendees of the meeting included Mr. Gong Li, Vice President of Jointown; Ms. Zhang Meiqin, General Manager of the Active Pharmaceutical Ingredients Division; Ms. Fu Qian, Deputy General Manager of Jiuxin Clinic under Jointown's Health Group; Mr. Liu Hui, Deputy General Manager of Quanqing Health; Mr. Wang Xiaoyan, Deputy General Manager of the Group Procurement Division; and Ms. Liu Yingmei, Sales Director of BGM Group. About BGM Group Ltd BGM Group Ltd,headquartered in Chengdu, China, is an innovative company dedicated to the fields of biopharmaceuticals, bio-extraction, and medical health. Our current product range includes oxytetracycline APIs, licorice preparations, and crude heparin sodium. The oxytetracycline API not only provides raw materials for pharmaceutical companies to produce human antibiotics but also supports the global breeding and livestock industries to ensure the safety of poultry and seafood. The crude heparin sodium, after processing by downstream companies, is transformed into refined heparin sodium and heparin sodium injection solutions, which are major anticoagulants. Licorice preparations, such as compound licorice lozenges, are used as cough suppressants and supplied to retail pharmacies. For more information, visit the Company's website at: Forward-looking Statements This news release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will", "expects", "anticipates", "future", "intends", "plans", "believes", "estimates", "target", "going forward", "outlook" and similar statements. Such statements are based upon management's current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's control, which may cause the Company's actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law. For investor and media inquiries, please contact: [email protected] SOURCE BGM Group Ltd WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

07 Nov 2024

·www.rovi.es

First nine months 2024 results press release

Operating revenue in the first nine months of 2024 was 564.6 million euros, a 5% decrease on the first nine months of 2023, mainly due to the performance of the contract development and manufacturing business ("CDMO"). This division generated (i) lower revenues from the manufacture of the COVID-19 vaccine in comparison to the first nine months of 2023, when ROVI had booked higher encone related to the production of the "pandemic" COVID-19 vaccine; and (ii) lower revenues related to the activities carried out to prepare the plant for production of the vaccine under the agreement with Moderna. However, CDMO sales increased by 16% to 134.4 million euros in the third quarter of 2024 compared to the third quarter of 2023, as a result of (i) higher revenue from existing customers (excluding Moderna); and (ii) higher revenue related to production of the COVID-19 vaccine due to a more concentrated seasonality in the third quarter. It should likewise be noted that the third quarter of 2024 is expected to be the strongest of the year in terms of CDMO sales performance. Positive evolution of Okedi® (Risperidone ISM®), sales of which increased 126% compared to the first nine months of 2023, totalling 20.3 million euros. ROVI announces that Risvan® (Risperidone ISM®), a product indicated for the treatment of schizophrenia in adults, will not be marketed in the United States, following an assessment of the uncertainties and opportunities associated to this launch. ROVI has, therefore, chosen to focus on the European development of Okedi® and expects this product to reach global potential sales of between 100 and 200 million euros in upcoming years. Sales of the heparin franchise (low-molecular-weight heparins (LMWH) and other heparins) decreased by 2% to 177.8 million euros in the first nine months of 2024, mainly due to lower orders from enoxaparin partners. Bemiparin sales, however, increased by 6% to 71.1 million euros in the first nine months of 2024. Additionally, ROVI forecasts full-year sales of bemiparin to increase by a low-single-digit percentage in 2024 compared to 2023, and the fourth quarter of 2024 to be the strongest quarter of the year in terms of enoxaparin sales, as a higher volume of orders from partners is expected. Good performance of Neparvis®, sales of which increased by 13% in the first nine months of 2024 compared to the same period of 2023, rising to 38.1 million euros. Gross margin was 63.6% in the first nine months of 2024, an increase of 4.7 percentage points on the first nine months of 2023. This increase was mainly due to: (i) the decrease in the contribution to the manufacturing business (CDMO) of revenue relating to activities to prepare the plant to produce medicines under the agreement with Moderna, which contributed lower margins to Group sales; (ii) the increased contribution to the CDMO business by existing customers (excluding Moderna), which contributed higher margins; and (iii) the increased contribution of sales of Okedi®, which likewise added higher margins. EBITDA margin increased 0.8 percentage point to 29.6% in the first nine months of 2024 from 28.8% in the same period of 2023. Net profit was 113.5 million euros in the first nine months of 2024. The ROVI General Shareholders Meeting, held on 24 June 2024, approved the payment of a gross dividend of 1.1037 euros per share; which represents approximately a 35% pay-out. This dividend was paid on 10 July 2024. Effective 13 September 2024, ROVI delisted 2,780,395 shares from the Stock-Exchange Interconnection System (Sistema de Interconexión Bursátil) and the Madrid, Barcelona, Bilbao and Valencia Stock Exchanges. As a result, the share capital of ROVI is now EUR 3,074,145.72, divided into 51,235,762 ordinary shares. By redeeming these shares, the shareholders have automatically increased their percentage interest in the capital stock. OUTLOOK For 2024, ROVI expects its operating revenue to decrease by a mid-single-digit percentage in comparison with 2023. For 2025, ROVI expects its operating revenue to decrease by a mid-single-digit percentage in comparison with 2024. Notwithstanding, this guidance is calculated using certain factors that could be relevant to the estimates and that are difficult to specify at the present time. They include, among others, the following: First, the 2024 vaccination campaigns, for flu and COVID-19, are still in progress and, as of today’s date, the Company is unable to forecast how the demand and production might evolve for the vaccination campaigns that will take place in 2025. Second, it is hoped that the expansion of the compounding, aseptic filling, inspection, labelling and packaging capacities at the ROVI facilities in Madrid and the current high market demand for contract manufacturing services (CDMO) will favour obtaining new customers, with the resulting sales impact. This would have to be considered but is impossible to estimate at this time.

VaccineFinancial StatementClinical Result

100 Deals associated with Heparin Sodium

External Link

KEGG	Wiki	ATC	Drug Bank
D02112	Heparin Sodium	S01XA14 B01AB01 C05BA03	DBSALT000417

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Angina, Unstable	Thailand	Shenzhen Techdow Pharmaceutical Co., Ltd.	02 Apr 2024
Non-Q wave myocardial infarction	Thailand	Shenzhen Techdow Pharmaceutical Co., Ltd.	02 Apr 2024
ST Elevation Myocardial Infarction	Thailand	Shenzhen Techdow Pharmaceutical Co., Ltd.	02 Apr 2024
Thromboembolism	United States	Pfizer Inc.	21 Jul 2011
Venous Thromboembolism	United States	Pfizer Inc.	21 Jul 2011
Thrombosis	Japan	Terumo Corp.	15 Mar 2002
Thrombophlebitis	Australia	Pfizer Australia Pty Ltd.	16 Aug 1991
Vascular occlusive disease	Australia	Pfizer Australia Pty Ltd.	16 Aug 1991
Atrial Fibrillation	United States	Hospira, Inc.	31 Jan 1984
Catheter blockage	United States	Baxter Healthcare Corp.	28 Apr 1982
Disseminated Intravascular Coagulation	United States	Fresenius Kabi USA LLC	10 Feb 1978
Blood Coagulation Disorders	United States	Fresenius Kabi USA, Inc.	22 Feb 1972
Embolism	United States	Fresenius Kabi USA, Inc.	22 Feb 1972
Pulmonary Embolism	United States	Fresenius Kabi USA, Inc.	22 Feb 1972
Venous Thrombosis	United States	Fresenius Kabi USA, Inc.	22 Feb 1972

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Catheter-Related Infections	Phase 3	United States	CorMedix, Inc.	-
Acute Coronary Syndrome	Phase 2	United States	Regado Biosciences, Inc.	01 Jul 2009
Acute Coronary Syndrome	Phase 2	France	Regado Biosciences, Inc.	01 Jul 2009
Acute Coronary Syndrome	Phase 2	Germany	Regado Biosciences, Inc.	01 Jul 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04743011 (EnHanCed, CTgov)	Phase 1/2	COVID-19	27	Placebo (Placebo)	vvdmlokupl(bnaeojnaou) = yfwalzgqgy jptfgdcdjx (hvhiwlasun, treatlgljl - iepmuknfdj) View more	-	15 Oct 2024
				Heparin sodium (Heparin Sodium)	vvdmlokupl(bnaeojnaou) = riehafswrr jptfgdcdjx (hvhiwlasun, ooyypbkntu - ectuyukxpu) View more
AAN2024	Not Applicable	Acute Ischemic Stroke	-	Patients receiving unfractionated heparin	oxgcjdvdig(nbpecutblj) = orwcfyicri lkjlmcnmhj (vtwnpggwya ) View more	-	09 Apr 2024
NCT02517307 (CTgov)	Not Applicable	Trifunctional Protein Deficiency With Myopathy and Neuropathy \| Medium Chain Acyl CoA Dehydrogenase Deficiency \| Carnitine Palmitoyltransferase II Deficiency, Late-Onset ... View more	41	Hyperinsulinemic euglycemic clamp+Glycerol/Saline (Glycerol/Saline FAOD)	mdhahyxlby(iwdebzcmaa) = ajfnyawtfe yvhamalmaa (wtcqgwhjgp, 244) View more	-	30 Jan 2024
				Hyperinsulinemic euglycemic clamp+Heparin+Intralipid (Intralipid FAOD)	mdhahyxlby(iwdebzcmaa) = wswflyoryn yvhamalmaa (wtcqgwhjgp, 297) View more
ASH2023	Not Applicable	Catheter related thrombosis	195	Full-dose LMWH	nbazqobqus(bvtwfeomaf) = yxuxefhxpt owuafbwyyw (enlglismvs )	-	11 Dec 2023
				Partial-dose LMWH	nbazqobqus(bvtwfeomaf) = nwmvpqzxmu owuafbwyyw (enlglismvs )
ASH2023	Not Applicable	Acute Lymphoblastic Leukemia	62	LMWH enoxaparin (1mg/kg/day)	rnxprbfmcs(lzdrvqkfua) = tntetnlkca husyfcrpjv (shbzmvtvtv )	-	10 Dec 2023
SGO2023	Not Applicable	Endometrial Carcinoma	-	prophylactic anticoagulation (No pharmacologic prophylaxis (NP))	hcsxjiqjeu(kahkybfgon) = admkncalfc fnfcqygrok (gmfqvlfhzp ) View more	-	01 Sep 2023
				Prophylactic enoxaparin (pEnox)	hcsxjiqjeu(kahkybfgon) = sdayxxwqug fnfcqygrok (gmfqvlfhzp ) View more
DEXHEP study (ISTH2023)	Not Applicable	PF4	165	Patients receiving unfractionated heparin with citrated tubes	sejlqyidpw(zibplqfdsg) = whtwbnykqu rghpsokwrb (dahiljecmz, +301 - +406)	-	24 Jun 2023
ASN2022	Not Applicable	-	6	Heparin sodium (Hep) full dose	vvkpzmbwqf(xhrvihwgwn) = jgzgpkieov fpldjhhyhx (seeklcdeaf )	Positive	06 Nov 2022
				Heparin sodium (Hep) 50% reduced dose	vvkpzmbwqf(xhrvihwgwn) = hwyxdixlfc fpldjhhyhx (seeklcdeaf )
EADV2022	Not Applicable	-	14	Intralesional heparin sodium	dbspzftgna(jwujupsjbz) = oxqhisssey vtwihsyiqi (oatyglvbmm ) View more	Positive	07 Sep 2022
ESC2022	Not Applicable	-	-	unfractionated heparin	zmlotxfcdo(jbfyjsmpgu) = lqnlefapeg vddydykhwt (xscuhyhbem ) View more	-	27 Aug 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis